Clinical Trials Browser

Phase 2 × Uterine Cervical Neoplasms × CTLA-4 Antigen × Clear all

NCT01693783 2022-11-08

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

Phase 2 Completed

42 enrolled 12 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Phase 2 Withdrawn

DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms